Printer Friendly

WARNER-LAMBERT VOLUNTARILY RECALLING SELECT DRUGS FROM DIRECT ACCOUNTS

 MORRIS PLAINS, N.J., Dec. 21 /PRNewswire/ -- Warner-Lambert Company (NYSE: WLA) today announced that as part of its ongoing discussions with the Food and Drug Administration, aimed at resolving manufacturing compliance issues primarily at its Puerto Rico facilities, it will be voluntarily recalling certain pharmaceutical products from direct accounts until such time as its manufacturing processes have been revalidated in accordance with FDA standards.
 The company said it is in continuing dialogue with the FDA regarding these administrative issues and emphasized that the recalls do not involve any safety concerns and do not extend to the patient level. As part of its effort, the company has retested hundreds of lots of marketed products and has demonstrated that all are within specifications. Substantial progress has already been made in the re- validation process.
 The recall is limited to Centrax, Ergostat, Estrovis, Norlestrin, Norlutin, Pyridium, Norlutate and Tedral.
 Warner-Lambert indicated that the costs involved in this effort would not prevent it from achieving the previously stated EPS gain of 15 percent it expects in 1992. The company also said that, on the basis of its current planning assumptions, it continues to be confident in its ability to generate double digit earnings growth in 1993.
 Warner-Lambert is a worldwide company devoted to discovering, developing, manufacturing and marketing quality health care and consumer products. It employs approximately 34,000.
 -0- 12/21/92
 /CONTACT: Peter Wolf (media), 201-540-6696, and Stephen Mock (investors), 201-540-6916, both of Warner-Lambert/
 (WLA)


CO: Warner-Lambert Company ST: New Jersey IN: MTC SU:

SH -- NY005 -- 8615 12/21/92 09:03 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 21, 1992
Words:261
Previous Article:FIRST IN A NEW CLASS OF PRESCRIPTION SLEEP AIDS APPROVED FOR MARKETING
Next Article:CINCINNATI MILACRON TO BUY GTE'S VALENITE SUBSIDIARY; SAYS INDUSTRIAL CONSUMABLE MAKER IS 'EXCELLENT FIT'
Topics:


Related Articles
WARNER-LAMBERT ACHIEVES RECORD SALES; RAISES DIVIDEND 16 PERCENT
W-L RECEIVES LETTER FROM FDA ON LOPID SR, CALLING INTO QUESTION COMPANY'S ABILITY TO OBTAIN TIMELY APPROVAL FOR CERTAIN INDICATIONS
WARNER-LAMBERT REPORTS RECORD SALES AND EARNINGS IN SECOND QUARTER
WARNER-LAMBERT REPORTS RECORD SALES IN THIRD QUARTER
WARNER-LAMBERT, WELLCOME AND GLAXO ANNOUNCE STRATEGIC ALLIANCES
WARNER-LAMBERT AND AVID THERAPEUTICS TO COLLABORATE ON HEPATITIS B DRUGS
WARNER-LAMBERT REPORTS THIRD-QUARTER SALES AND EARNINGS
LEUKOSITE ENTERS INTO AGREEMENT WITH WARNER-LAMBERT ON ANTI-INFLAMMATORY DRUGS
Hackard, Holt & Heller Files Lawsuit in Boston Alleging Liver Damage From Diabetes Drug.
California Verdict Finds Warner-Lambert Not Liable in Rezulin Trial.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters